Harpoon Therapeutics has selected CMC Biologics to develop and manufacture three molecules for cancer treatments at the CDMO’s facilities in California and Washington State, US.
Catalent has partnered with US non-profit PATH for antibody discovery using the CDMO’s GPEx cell line platform, funded by PATH’s Malaria Vaccine Initiative (MVI).
Single-use manufacturing runs have been limited to 2,000L, but CMC Biologics says it will be able to offer 12,000L of commercial scale through its bioreactor configuration platform.
Contract manufacturer CMC Biologics and Zymeworks have entered into a master services agreement whereby CMC will perform the process development, formulation development and cGMP clinical manufacturing of a recombinant human IgG1 bi-specific (heterodimeric)...